DNER and colorectal carcinoma: To explore the mechanisms driving synergy between BET and MEK inhibition we first evaluated gene expression changes in the CRC cell line RKO (BRAF V600E; NF1 V2205A) following treatment with GSK525762, trametinib, and the combination (Supplemental Figure S11A-B).